Intensified or accelerated dosing regimens with infliximab (Remicade) did not improve outcomes compared with the standard regimen in patients with steroid-refractory acute severe ulcerative colitis ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. After previously discontinuing infliximab, 35% of ...

Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for ...

Please provide your email address to receive an email when new articles are posted on . The use of infliximab in patients with a deceased donor kidney transplant led to increased infections and did ...

Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, according to research ...

The study, with a small sample size, said most patients who take infliximab for more than 6 years report continued efficacy. Infliximab can be safe and effective as a long-term therapy in people with ...

Infliximab is a medication used to reduce the symptoms and signs of several chronic inflammatory disorders. It is approved for the treatment of Crohn’s disease, rheumatoid arthritis, psoriasis, ...

Editor's Note: In August, a Medscape reader wrote in with the question, "Is Infliximab Appropriate for Stricturing-Type Crohn's Disease?" Gastroenterologist Bret A. Lashner, MD, responded to this ...

New users of infliximab and adalimumab who had moderate to severe psoriasis exhibited an increased risk of hospitalization due to serious infection compared with etanercept users, with use of ...

Infliximab is a monoclonal antibody that is administered intravenously to treat patients with chronic inflammatory diseases including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, plaque ...

A Pediatric Blood and Marrow Transplant Consortium (PBMTC) survey was undertaken in early 2002 to capture information about current clinical practice using infliximab in children with GVHD to plan a ...

Infliximab retards progression of radiographically visible joint damage in patients with rheumatoid arthritis (RA). Vis and colleagues investigated whether infliximab can also prevent osteoporosis in ...